Published • loading... • Updated
FDA Grants Orphan Drug Designation to COAGADEX for Acquired Factor X Deficiency Linked to AL Amyloidosis
Summary by GeneOnline News
46 Articles
46 Articles
Johnson City Press+44 Reposted by 44 other sources
Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety
FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Coagulation Factor X human (tradename COAGADEX) for the treatment of acquired…
Coverage Details
Total News Sources46
Leaning Left6Leaning Right5Center21Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
L 19%
C 66%
15%
Factuality
To view factuality data please Upgrade to Premium
